Jun 2026 (Q3 FY26) — Aug 5, 2026
Cencora Q3 FY26 — Strong Specialty Performance Drives Double-Digit Operating Income and Raised EPS Guidance
Read the full callCencora (COR) earnings
- Jun 2026
- Jun 2026 (Q3 FY26)
- Sep 2025
Cencora earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 84,755 | +5.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 1.3 | +0.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 764 | +11.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
7 of 7 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Opportunistic share repurchase target | $1 billion worth of shares by calendar year-end | Mar 2026 | $1 billion of share repurchases in the quarter at an average price of $268 per share | Achieved |
| Adjusted diluted EPS growth (FY26) | $17.45 to $17.75, representing growth of 9% to 11% | Sep 2025 | we are pleased to raise our full year adjusted EPS guidance range to $17.75 to $17.95, up from $17.70 to $17.90 | Revised Up |
| Adjusted free cash flow (FY26) | approximately $3 billion | Sep 2025 | Our full year adjusted free cash flow guidance of approximately $3 billion remains unchanged | On Track |
25 of Cencora, Inc.'s 32 targets are still open. See which are on track and which have gone quiet. The 3 above are the free sample; 29 more targets are in the full ledger.
Claimed
- Adjusted operating income grew 17% to $1.2 billion, driven by U.S. Healthcare Solutions and International segments.
- Adjusted EPS grew 12%, leading to raised fiscal 2026 guidance to $17.75-$17.95, supported by $1 billion in share repurchases.
- U.S. Healthcare Solutions segment operating income increased 16% to $966 million, with strong performance from MSO platforms (One Oncology, RCA).
- International Healthcare Solutions operating income grew 21% (23% constant currency) to $166 million, driven by European distribution and specialty logistics.
- GLP-1 sales increased by $2.3 billion year-over-year, contributing to U.S. revenue growth.
Qualified
- Manufacturer list price reductions represented a $2.4 billion headwind to U.S. revenue growth.
- Net interest expense increased by $59 million to $141 million, primarily due to debt for the One Oncology acquisition.
- Potential $0.35 EPS headwind in FY27 from the MWI Animal Health divestiture if closed at the midpoint of the fiscal year.
Price
$340 −0.27% · −$0.92
Performance +4.7% 1Y
1Y: $324.69 on 17 Oct 2025 → $340. High $374.75 (25 Nov 2025), low $252.74 (6 May 2026).
- Previous close
- $340.92
- 52-week range
- $252.74 – $374.75
- One year
- +3.85%
Overview
- Symbol
- COR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
7 of 7 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Opportunistic share repurchase target | $1 billion worth of shares by calendar year-end | Mar 2026 | $1 billion of share repurchases in the quarter at an average price of $268 per share | Achieved |
| Adjusted diluted EPS growth (FY26) | $17.45 to $17.75, representing growth of 9% to 11% | Sep 2025 | we are pleased to raise our full year adjusted EPS guidance range to $17.75 to $17.95, up from $17.70 to $17.90 | Revised Up |
| Adjusted free cash flow (FY26) | approximately $3 billion | Sep 2025 | Our full year adjusted free cash flow guidance of approximately $3 billion remains unchanged | On Track |
Claimed
- Adjusted operating income grew 17% to $1.2 billion, driven by U.S. Healthcare Solutions and International segments.
- Adjusted EPS grew 12%, leading to raised fiscal 2026 guidance to $17.75-$17.95, supported by $1 billion in share repurchases.
- U.S. Healthcare Solutions segment operating income increased 16% to $966 million, with strong performance from MSO platforms (One Oncology, RCA).
- International Healthcare Solutions operating income grew 21% (23% constant currency) to $166 million, driven by European distribution and specialty logistics.
- GLP-1 sales increased by $2.3 billion year-over-year, contributing to U.S. revenue growth.
Qualified
- Manufacturer list price reductions represented a $2.4 billion headwind to U.S. revenue growth.
- Net interest expense increased by $59 million to $141 million, primarily due to debt for the One Oncology acquisition.
- Potential $0.35 EPS headwind in FY27 from the MWI Animal Health divestiture if closed at the midpoint of the fiscal year.
The full ledger
Open Cencora, Inc.’s full ledger
A free account opens 5 company ledgers a month. All 32 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q2 FY26) — May 6, 2026
Cencora Q2 FY26 — EPS +7.5%, EPS/OI guidance raised, buybacks resume amid transitory revenue headwinds
Read the full callDec 2025 (Q1 FY26) — Feb 4, 2026
Cencora Q1 FY26 — Strong Specialty Performance and OneOncology Acquisition Drive Raised Guidance
Read the full callEvery analysed call
Cencora earnings calls (COR)
Financials
What the filings say
Net profit, year on year: +11% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 79,050 | 81,487 | 75,454 | 80,664 | 83,729 | 85,932 | 78,356 | 84,755 |
| Operating profit | 127 | 706 | 1,036 | 868 | 19 | 760 | 1,143 | 1,120 |
| Operating margin | 0.2% | 0.9% | 1.4% | 1.1% | 0.0% | 0.9% | 1.5% | 1.3% |
| Other income | 20 | -58 | -4 | 110 | -128 | 21 | 1,086 | 17 |
| Profit before tax | 125 | 620 | 929 | 896 | -187 | 709 | 2,089 | 996 |
| Tax rate | 94.0% | 20.4% | 22.8% | 23.0% | −78.1% | 20.1% | 22.0% | 22.1% |
| Net profit | 3 | 489 | 718 | 687 | -340 | 560 | 1,641 | 764 |
| EPS ($ per share) | — | 2.52 | 3.70 | 3.55 | — | 2.88 | 8.44 | 3.95 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 3,721 | 4,235 | 518 | 1,671 | 2,978 | 4,324 | 5,417 | 6,534 |
| Total liabilities | 34,620 | 36,179 | 45,114 | 56,753 | 56,489 | 61,892 | 66,315 | 74,843 |
| Fixed assets | 1,892 | 1,771 | 1,485 | 2,163 | 2,135 | 2,135 | 2,181 | 2,539 |
| Total assets | 37,670 | 39,172 | 44,275 | 57,338 | 56,561 | 62,559 | 67,102 | 76,590 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,411 | 2,344 | 2,207 | 2,667 | 2,703 | 3,911 | 3,485 | 3,875 |
| Cash from investing | -1,111 | -376 | -380 | -6,142 | -368 | -2,602 | -618 | -4,977 |
| Cash from financing | -243 | -1,087 | -604 | 1,953 | -1,753 | -2,222 | -2,331 | 2,249 |
| Net cash flow | 57 | 882 | 1,224 | -1,528 | 523 | -841 | 545 | 1,097 |
| Capital expenditure | -336 | -310 | -370 | -438 | -496 | -458 | -487 | -668 |
| Free cash flow | 1,075 | 2,034 | 1,837 | 2,228 | 2,207 | 3,453 | 2,998 | 3,207 |
COR revenue by segment
| Segment | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| US Healthcare Solutions | 91% | 91% | 91% | 90% | 91% | 89% | 88% | 88% | +2.7% |
| International Healthcare Solutions | 10% | 9% | 10% | 10% | 9% | 9% | 10% | 9% | -1.4% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
109 filings between Oct 20, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
$2.31M
3 purchases by 2 insiders
Sales
$16.72M
13 sales by 5 insiders
62% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 33
- Award — granted as compensation
- 29
- Option exercise — converted options into shares
- 29
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Mauch Robert P. | — | $8.92M | Feb 20, 2026 |
| Campbell Elizabeth S | — | $4.81M | Aug 24, 2026 |
| DURCAN DERMOT MARK | $2.16M | — | Jun 18, 2026 |
| Krikorian Lazarus | — | $2.00M | Oct 1, 2026 |
| Battaglia Silvana | — | $578.6K | Dec 19, 2025 |
| GREENBERG LON R | — | $411.3K | Sep 16, 2026 |
| Tyler Lauren M | $148.6K | — | Jun 22, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | SANCHEZ ROBERT E Director | Award | 275 | — |
| Oct 1, 2026 | Krikorian Lazarus SVP & Chief Accounting Officer | Sale 10b5-1 plan | 986 | $298.9K |
| Sep 16, 2026 | GREENBERG LON R Director | Sale | 1,280 | $411.3K |
| Sep 1, 2026 | Krikorian Lazarus SVP & Chief Accounting Officer | Sale 10b5-1 plan | 985 | $321.1K |
| Aug 24, 2026 | Campbell Elizabeth S Executive Vice President | Sale | 11,300 | $3.66M |
| Jul 31, 2026 | NALLY DENNIS M Director | Award | 113 | $35.2K |
| Jul 31, 2026 | Cooper Ellen Director | Award | 97 | $30.2K |
| Jul 31, 2026 | Tyler Lauren M Director | Award | 97 | $30.2K |
| Jun 30, 2026 | Battaglia Silvana Executive Vice President | Award | 58 | $14.0K |
| Jun 30, 2026 | Campbell Elizabeth S Executive Vice President | Award | 50 | $12.0K |
| Jun 22, 2026 | Tyler Lauren M Director | Purchase | 550 | $148.6K |
| Jun 18, 2026 | DURCAN DERMOT MARK Director | Purchase | 4,000 | $1.10M |
| May 28, 2026 | DURCAN DERMOT MARK Director | Purchase | 4,000 | $1.07M |
| May 1, 2026 | Tyler Lauren M Director | Award | 99 | $30.1K |
| May 1, 2026 | Cooper Ellen Director | Award | 99 | $30.1K |
| May 1, 2026 | NALLY DENNIS M Director | Award | 116 | $35.3K |
| Mar 11, 2026 | Battaglia Silvana Executive Vice President | Option exercise | 8,415 | $0 |
| Mar 11, 2026 | Cleary James F Chief Financial Officer | Tax withheld | 5,409 | $1.89M |
| Mar 11, 2026 | Cleary James F Chief Financial Officer | Option exercise | 12,623 | $0 |
| Mar 11, 2026 | Campbell Elizabeth S Executive Vice President | Tax withheld | 5,842 | $2.05M |
| Mar 11, 2026 | Campbell Elizabeth S Executive Vice President | Option exercise | 12,623 | $0 |
| Mar 11, 2026 | Battaglia Silvana Executive Vice President | Tax withheld | 3,673 | $1.29M |
| Mar 5, 2026 | Tyler Lauren M Director | Award | 557 | $200.1K |
| Mar 5, 2026 | Clyburn Frank Director | Award | 557 | $200.1K |
| Mar 5, 2026 | NALLY DENNIS M Director | Award | 557 | $200.1K |
| Mar 5, 2026 | Kim Lorence H. Director | Award | 557 | $200.1K |
| Mar 5, 2026 | Cooper Ellen Director | Award | 557 | $200.1K |
| Mar 5, 2026 | Ryerkerk Lori Director | Award | 557 | $200.1K |
| Mar 5, 2026 | GREENBERG LON R Director | Award | 557 | $200.1K |
| Mar 5, 2026 | Miller Redonda Director | Award | 557 | $200.1K |
| Mar 5, 2026 | DURCAN DERMOT MARK Director | Award | 905 | $325.1K |
| Mar 5, 2026 | Baumann Werner Director | Award | 557 | $200.1K |
| Feb 20, 2026 | Mauch Robert P. President & CEO | Sale 10b5-1 plan | 3,762 | $1.35M |
| Feb 20, 2026 | Mauch Robert P. President & CEO | Option exercise 10b5-1 plan | 3,762 | $323.9K |
| Feb 18, 2026 | Mauch Robert P. President & CEO | Sale 10b5-1 plan | 1,333 | $479.2K |
| Jan 30, 2026 | Tyler Lauren M Director | Award | 84 | $30.2K |
| Jan 30, 2026 | NALLY DENNIS M Director | Award | 98 | $35.2K |
| Jan 30, 2026 | Cooper Ellen Director | Award | 66 | $23.7K |
| Jan 30, 2026 | Cooper Ellen Director | Award | 69 | $24.8K |
| Jan 20, 2026 | Mauch Robert P. President & CEO | Sale 10b5-1 plan | 5,096 | $1.81M |
| Jan 20, 2026 | Mauch Robert P. President & CEO | Option exercise 10b5-1 plan | 3,763 | $324.0K |
| Dec 31, 2025 | Battaglia Silvana Executive Vice President | Award | 27 | $7.9K |
| Dec 31, 2025 | Campbell Elizabeth S Executive Vice President | Award | 34 | $9.6K |
| Dec 19, 2025 | Battaglia Silvana Executive Vice President | Sale | 1,677 | $578.6K |
| Dec 19, 2025 | Campbell Elizabeth S Executive Vice President | Sale | 3,351 | $1.15M |
| Dec 18, 2025 | Mauch Robert P. President & CEO | Sale 10b5-1 plan | 5,096 | $1.75M |
| Dec 18, 2025 | Mauch Robert P. President & CEO | Option exercise 10b5-1 plan | 3,763 | $324.0K |
| Dec 17, 2025 | Cleary James F Chief Financial Officer | Tax withheld | 26,952 | $9.28M |
| Dec 17, 2025 | NALLY DENNIS M Director | Gift | 1,173 | $0 |
| Dec 17, 2025 | Cleary James F Chief Financial Officer | Option exercise | 45,154 | $3.89M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Cencora, Inc.
Free account. Everything above stays public.
Write why you follow Cencora, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading